Laboratory of Dr. Lydie Trautmann
Dr. Lydie Trautmann’s laboratory is focused on understanding the early immunological events occurring after infection and vaccination. Two different areas of research focused on CD8 T cells are currently being pursued:
|
Research Projects
Analyzing early immunological events in HIV infection to define how HIV infection leads to T cell dysfunction and lack of T cell memory.
The first immunological events that occur after HIV exposure might play a crucial role in the viral control and determine the disease outcome. Our studies highlighted the role of PD-1 in T-cell dysfunction in the chronic phase of infection and also showed a pronounced T-cell dysfunction in the early phase of HIV infection. Using a multi-pronged approach, we are dissecting the mechanisms of the early immune response to the virus in acutely infected individuals and the TCR repertoire as well as in different in vitro models using primary cells from blood and mucosal tissues to define how HIV infection leads to T cell dysfunction. The identification of mechanisms leading to immune dysfunction and protection should provide clues for strategies to control viral replication and dissemination of HIV.
Characterizing the effector and memory immune responses to yellow fever and influenza vaccines.
Successful vaccines induce the generation of specific immune memory that can provide lifelong protection. Developed empirically in the 1930's, the yellow fever vaccine represents one of the most successful vaccines ever made. Dr. Sékaly's group and others have recently used this vaccine to determine a gene expression signature of effective protection. We are using highly sensitive techniques to define mechanisms and key factors that would be predictive of protective immunity. We are comparing the response to yellow fever vaccine between European and Ugandan populations. We are analyzing the effector and memory immune responses as well as their TCR repertoire in individuals receiving a first and second immunization of influenza or yellow fever vaccines. Understanding the determinants of an efficient immune response upon revaccination will be crucial to design new T-cell based vaccine strategies.
The first immunological events that occur after HIV exposure might play a crucial role in the viral control and determine the disease outcome. Our studies highlighted the role of PD-1 in T-cell dysfunction in the chronic phase of infection and also showed a pronounced T-cell dysfunction in the early phase of HIV infection. Using a multi-pronged approach, we are dissecting the mechanisms of the early immune response to the virus in acutely infected individuals and the TCR repertoire as well as in different in vitro models using primary cells from blood and mucosal tissues to define how HIV infection leads to T cell dysfunction. The identification of mechanisms leading to immune dysfunction and protection should provide clues for strategies to control viral replication and dissemination of HIV.
Characterizing the effector and memory immune responses to yellow fever and influenza vaccines.
Successful vaccines induce the generation of specific immune memory that can provide lifelong protection. Developed empirically in the 1930's, the yellow fever vaccine represents one of the most successful vaccines ever made. Dr. Sékaly's group and others have recently used this vaccine to determine a gene expression signature of effective protection. We are using highly sensitive techniques to define mechanisms and key factors that would be predictive of protective immunity. We are comparing the response to yellow fever vaccine between European and Ugandan populations. We are analyzing the effector and memory immune responses as well as their TCR repertoire in individuals receiving a first and second immunization of influenza or yellow fever vaccines. Understanding the determinants of an efficient immune response upon revaccination will be crucial to design new T-cell based vaccine strategies.
Contact Information
Lydie Trautmann, Ph.D.
Assistant Member
Vaccine & Gene Therapy Institute of Florida
9801 SW Discovery Way
Port St. Lucie, FL 34987
Tel: (772) 345-5671
Fax: (772) 345-0625
Email: [email protected]
Lab Members
Tel: (772) 345-5683
Fax: (772) 345-0625
Divya Srinivasan [email protected]
Pearline Ngauv [email protected]
Publications
Trautmann L, Mbitikon-Kobo FM, Goulet JP, Peretz Y, Shi Y, Van Grevenynghe J, Procopio F, Boulassel MR, Routy JP, Chomont N, Haddad EK and Sekaly RP. Profound Metabolic, Functional and Cytolytic Differences Characterize HIV-Specific CD8 T Cells in Primary and Chronic HIV Infection. Blood 2012 120(17):3466-77
Janbazian L, Price DA, Canderan G, Filali-Mouhim A, Asher TE, Ambrozak DR, Scheinberg P, Boulassel MR, Routy JP, Koup RA, Douek DC, Sekaly RP, Trautmann L.
Clonotype and Repertoire Changes Drive the Functional Improvement of HIV-Specific CD8 T Cell Populations under Conditions of Limited Antigenic Stimulation.
J Immunol. 2012 Feb 1;188(3):1156-67. Epub 2011 Dec 30.
Mbitikon-Kobo FM, Bonneville M, Sekaly RP, Trautmann L. Ex vivo measurement of the cytotoxic capacity of human primary antigen-specific CD8 T cells.
J Immunol Methods. 2012 Jan 31;375(1-2):252-7. Epub 2011 Oct 5.
H. Perrin, G. Canderan, R.P. Sekaly, L. Trautmann. New approaches to design HIV-1 T cell vaccines. 2010. Current Opinion in HIV & AIDS.5:368-376.
E.A. Said, F.P. Dupuy, L. Trautmann, Y. Zhang, Y. Shi, M. El-Far, B.J. Hill, A. Noto, P. Ancuta, Y. Peretz, S.G. Fonseca, J. Van Grevenynghe, M.R. Boulassel, J. Bruneau, N.H. Shoukry, J.P. Routy, D.C. Douek, E.K. Haddad, R.P. Sekaly. PD-1 Induced IL-10 Production by Monocytes Impairs CD4 T-Cell Activation during HIV Infection. Nat Med 2010 Apr;16(4):452-9
N. Chomont, M. El-Far, P. Ancuta, L. Trautmann, F.A. Procopio, B. Yassine-Diab, G. Boucher, M.R. Boulassel, G. Ghattas, J. M Brenchley, T. W Schacker, B. J Hill, D. C Douek, J.P. Routy, E.K. Haddad, R.P. Sekaly. 2009. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009 Aug;15(8):893-900
Trautmann L. , L. Janbazian, N. Chomont, E.A. Said, S. Gimmig, B. Bessette, M.R. Boulassel, E. Delwart, H. Sepulveda, R. S Balderas, J.P. Routy, E.K. Haddad and R.P. Sekaly. 2006. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. Oct;12(10):1198-202
Trautmann L.,M. Rimbert, K. Echasserieau, X. Saulquin, B. Neveu, J. Dechanet, V. Cerundolo, M. Bonneville. 2005. Selection of T cell clones expressing high-affinity public TCRs within Human cytomegalovirus-specific CD8 T cell responses. J Immunol. 175(9):6123-32
Trautmann L., N. Labarrière, F. Jotereau, V. Karanikas, N.Gervois, T. Connerotte, P. Coulie and M. Bonneville. 2002. Dominant TCR Va usage by virus and tumor reactive T cells with wide affinity ranges for their specific antigens. Eur J Immunol 32(11) : 3181-3190
Assistant Member
Vaccine & Gene Therapy Institute of Florida
9801 SW Discovery Way
Port St. Lucie, FL 34987
Tel: (772) 345-5671
Fax: (772) 345-0625
Email: [email protected]
Lab Members
Tel: (772) 345-5683
Fax: (772) 345-0625
Divya Srinivasan [email protected]
Pearline Ngauv [email protected]
Publications
Trautmann L, Mbitikon-Kobo FM, Goulet JP, Peretz Y, Shi Y, Van Grevenynghe J, Procopio F, Boulassel MR, Routy JP, Chomont N, Haddad EK and Sekaly RP. Profound Metabolic, Functional and Cytolytic Differences Characterize HIV-Specific CD8 T Cells in Primary and Chronic HIV Infection. Blood 2012 120(17):3466-77
Janbazian L, Price DA, Canderan G, Filali-Mouhim A, Asher TE, Ambrozak DR, Scheinberg P, Boulassel MR, Routy JP, Koup RA, Douek DC, Sekaly RP, Trautmann L.
Clonotype and Repertoire Changes Drive the Functional Improvement of HIV-Specific CD8 T Cell Populations under Conditions of Limited Antigenic Stimulation.
J Immunol. 2012 Feb 1;188(3):1156-67. Epub 2011 Dec 30.
Mbitikon-Kobo FM, Bonneville M, Sekaly RP, Trautmann L. Ex vivo measurement of the cytotoxic capacity of human primary antigen-specific CD8 T cells.
J Immunol Methods. 2012 Jan 31;375(1-2):252-7. Epub 2011 Oct 5.
H. Perrin, G. Canderan, R.P. Sekaly, L. Trautmann. New approaches to design HIV-1 T cell vaccines. 2010. Current Opinion in HIV & AIDS.5:368-376.
E.A. Said, F.P. Dupuy, L. Trautmann, Y. Zhang, Y. Shi, M. El-Far, B.J. Hill, A. Noto, P. Ancuta, Y. Peretz, S.G. Fonseca, J. Van Grevenynghe, M.R. Boulassel, J. Bruneau, N.H. Shoukry, J.P. Routy, D.C. Douek, E.K. Haddad, R.P. Sekaly. PD-1 Induced IL-10 Production by Monocytes Impairs CD4 T-Cell Activation during HIV Infection. Nat Med 2010 Apr;16(4):452-9
N. Chomont, M. El-Far, P. Ancuta, L. Trautmann, F.A. Procopio, B. Yassine-Diab, G. Boucher, M.R. Boulassel, G. Ghattas, J. M Brenchley, T. W Schacker, B. J Hill, D. C Douek, J.P. Routy, E.K. Haddad, R.P. Sekaly. 2009. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009 Aug;15(8):893-900
Trautmann L. , L. Janbazian, N. Chomont, E.A. Said, S. Gimmig, B. Bessette, M.R. Boulassel, E. Delwart, H. Sepulveda, R. S Balderas, J.P. Routy, E.K. Haddad and R.P. Sekaly. 2006. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. Oct;12(10):1198-202
Trautmann L.,M. Rimbert, K. Echasserieau, X. Saulquin, B. Neveu, J. Dechanet, V. Cerundolo, M. Bonneville. 2005. Selection of T cell clones expressing high-affinity public TCRs within Human cytomegalovirus-specific CD8 T cell responses. J Immunol. 175(9):6123-32
Trautmann L., N. Labarrière, F. Jotereau, V. Karanikas, N.Gervois, T. Connerotte, P. Coulie and M. Bonneville. 2002. Dominant TCR Va usage by virus and tumor reactive T cells with wide affinity ranges for their specific antigens. Eur J Immunol 32(11) : 3181-3190